Gwajin Arrow, Gaskiya, Bayanin NSCLC, pralsetinib
FDA ta amince da Pralsetinib don ciwon daji na huhu mara ƙarami tare da haɗakar halittar RET
Agusta 2023: Pralsetinib (Gavreto, Genentech, Inc.) An ba da izini akai-akai ta Cibiyar Abinci da Magunguna don manya marasa lafiya tare da ciwon daji na huhu na huhu (NSCLC), kamar yadda FDA ta ƙaddara.
CD20, Kolumvi, Farashin DLBCL, Gaskiya
Glofitamab-gxbm an amince da shi ta FDA don zaɓaɓɓen ƙwararrun ƙwayoyin lymphomas na B-cell da suka koma baya.
Yuli 2023: Hukumar Abinci da Magunguna ta ba da izini ga glofitamab-gxbm (Columvi, Genentech, Inc.) don sake dawowa ko ɓarnawar babban lymphoma B-cell, ba in ba haka ba (DLBCL, NOS) ko manyan ƙwayoyin B-cell ly.
Gaskiya, Lunsumio, mosunetozumab-axgb, lymphoma follicular refractory
Mosunetuzumab-axgb an ba da izinin hanzari don sake dawowa ko ƙwayar lymphoma follicular
Jan 2023: Mosunetuzumab-axgb (Lunsumio, Genentech, Inc.), CD20-directed CD3 T-cell engager don manya marasa lafiya tare da relapsed ko refractory follicular lymphoma (FL) bin biyu ko fiye zagaye na tsarin jiyya, rece.
alveolar taushi part sarcoma, Atezolizumab, tsarin kulawa na tsakiya, Gaskiya, Tecentriq
An amince da Atezolizumab ta FDA don sarcoma mai laushi na alveolar
Dec 2022: Atezolizumab (Tecentriq, Genentech, Inc.) an amince da shi ta Cibiyar Abinci da Magunguna (FDA) don manya da marasa lafiya na yara tare da sarcoma mai laushi mara kyau ko metastatic alveolar.
Burkitt lymphoma, Burkitt-kamar lymphoma, Farashin DLBCL, Gaskiya, Rituxan, Rituximab
Rituximab plus chemotherapy an amince da ita ta FDA don alamun ciwon daji na yara
Maris 2022: Hukumar Abinci da Magunguna ta amince da rituximab (Rituxan, Genentech, Inc.) tare da haɗin gwiwar chemotherapy don CD20-positive diffuse big B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma.
Atezolizumab, Gaskiya, Bayanin NSCLC, Tecentriq, Tsarin Kiwon Lafiya na Ventana, Farashin PD-L1
Atezolizumab an amince da ita ta FDA a matsayin magani na adjuvant don ciwon huhu mara ƙarami
Nov 2021: Hukumar Abinci da Magunguna ta amince da atezolizumab (Tecentriq, Genentech, Inc.) don maganin adjuvant a cikin marasa lafiya tare da mataki na II zuwa IIIA ciwon huhu mara ƙaranci (NSCLC) wanda ciwace-ciwacen su ya ƙunshi PD-L1 magana o..